Fig. 3: FTY720 induces cell cycle arrest and drives apoptosis in KMT2A-R leukemic cell lines.
From: SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML
A–G Proliferation curve of K562, Kasumi, THP1, MV411, SEM, Hb1119, and REH stably expressing eGFP, upon treatment with FTY720 for 6 days. GFP expression was used as quantitative reporter of cell proliferation. For each cell line, the same number of cells was plated at t0 and the GFP signal was measured with a fluorescent microplate reader every 2 days. Data show mean ± SD of triplicate wells and are representative of three independent experiments. 2-Way Anova Sydak’s multiple comparison test *p < 0.05; ** p < 0.01; **** p < 0.0001. H Cell cycle analysis performed on K562, Kasumi1, MV4,11 and THP1, upon 5 µM FTY720 treatment for 48 h. Data show mean ± SD of triplicate wells and are representative of two independent experiments. Two-tailed unpaired t test *p < 0.05. I Fraction of cells undergoing cell death (GFP-) upon 5 µM FTY720 treatment for 48 h. Data show mean ± SD of triplicate wells and are representative of three independent experiments. Two-tailed unpaired t test *p < 0.05; ****p < 0.0001.
